Can Arterial Spin-Labeling with Multiple Postlabeling Delays Predict Cerebrovascular Reserve?

References

1. 1.↵
   2. Derdeyn CP,
   3. Grubb RL Jr.,
   4. Powers WJ

   . Cerebral hemodynamic impairment: methods of measurement and association with stroke risk. Neurology 1999;53:251–59 doi:10.1212/WNL.53.2.251 pmid:10430410

   Abstract/FREE Full Text
2. 2.↵
   2. Wintermark M,
   3. Sesay M,
   4. Barbier E, et al

   . Comparative overview of brain perfusion imaging techniques. Stroke 2005;36:e83–99 doi:10.1161/01.STR.0000177884.72657.8b pmid:16100027

   Abstract/FREE Full Text
3. 3.↵
   2. Kim E,
   3. Sohn CH,
   4. Na DG, et al

   . Perfusion computed tomography evaluation of cerebral hemodynamic impairment in patients with unilateral chronic steno-occlusive disease: a comparison with the acetazolamide challenge 99mTc-hexamethylpropyleneamine oxime single-photon emission computed tomography. J Comput Assist Tomogr 2009;33:546–51 doi:10.1097/RCT.0b013e318188887d pmid:19638847

   CrossRefPubMed
4. 4.↵
   2. Barber PA,
   3. Consolo HK,
   4. Yang Q, et al

   . Comparison of MRI perfusion imaging and single photon emission computed tomography in chronic stroke. Cerebrovasc Dis 2001;11:128–36 doi:10.1159/000047624 pmid:11223665

   CrossRefPubMed
5. 5.↵
   2. Vagal AS,
   3. Leach JL,
   4. Fernandez-Ulloa M, et al

   . The acetazolamide challenge: techniques and applications in the evaluation of chronic cerebral ischemia. AJNR Am J Neuroradiol 2009;30:876–84 doi:10.3174/ajnr.A1538 pmid:19246526

   Abstract/FREE Full Text
6. 6.↵
   2. Sullivan HG,
   3. Kingsbury TB 4th.,
   4. Morgan ME, et al

   . The rCBF response to Diamox in normal subjects and cerebrovascular disease patients. J Neurosurg 1987;67:525–34 doi:10.3171/jns.1987.67.4.0525 pmid:3655890

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Komiyama M,
   3. Nishikawa M,
   4. Yasui T, et al

   . Reversible pontine ischemia caused by acetazolamide challenge. AJNR Am J Neuroradiol 1997;18:1782–84 pmid:9367331

   Abstract
8. 8.↵
   2. Zimmermann S,
   3. Achenbach S,
   4. Wolf M, et al

   . Recurrent shock and pulmonary edema due to acetazolamide medication after cataract surgery. Heart Lung 2014;43:124–26 doi:10.1016/j.hrtlng.2013.11.008 pmid:24388201

   CrossRefPubMed
9. 9.↵
   2. Her Y,
   3. Kil MS,
   4. Park JH, et al

   . Stevens-Johnson syndrome induced by acetazolamide. J Dermatol 2011;38:272–75 doi:10.1111/j.1346-8138.2010.00921.x pmid:21342230

   CrossRefPubMed
10. 10.↵
    2. Hu CY,
    3. Lee BJ,
    4. Cheng HF, et al

    . Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient. J Glaucoma 2015;24:e31–33 doi:10.1097/IJG.0000000000000185 pmid:25333610

    CrossRefPubMed
11. 11.↵
    2. Kelly TE,
    3. Hackett PH

    . Acetazolamide and sulfonamide allergy: a not so simple story. High Alt Med Biol 2010;11:319–23 doi:10.1089/ham.2010.1051 pmid:21190500

    CrossRefPubMed
12. 12.↵
    2. Alsop DC,
    3. Detre JA,
    4. Golay X, et al

    . Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med 2015;73:102–16 doi:10.1002/mrm.25197 pmid:24715426

    CrossRefPubMed
13. 13.↵
    2. Deibler AR,
    3. Pollock JM,
    4. Kraft RA, et al

    . Arterial spin-labeling in routine clinical practice, Part 1: technique and artifacts. AJNR Am J Neuroradiol 2008;29:1228–34 doi:10.3174/ajnr.A1030 pmid:18372417

    Abstract/FREE Full Text
14. 14.↵
    2. Alsop DC,
    3. Detre JA,
    4. Grossman M

    . Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000;47:93–100 pmid:10632106

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Haga S,
    3. Morioka T,
    4. Shimogawa T, et al

    . Arterial spin labeling perfusion magnetic resonance image with dual postlabeling delay: a correlative study with acetazolamide loading (123)I-iodoamphetamine single-photon emission computed tomography. J Stroke Cerebrovasc Dis 2016;25:1–6 doi:10.1016/j.jstrokecerebrovasdis.2015.08.025 pmid:26387043

    CrossRefPubMed
16. 16.↵
    2. Wang R,
    3. Yu S,
    4. Alger JR, et al

    . Multi-delay arterial spin labeling perfusion MRI in Moyamoya disease–comparison with CT perfusion imaging. Eur Radiol 2014;24:1135–44 doi:10.1007/s00330-014-3098-9 pmid:24557051

    CrossRefPubMed
17. 17.↵
    2. Yun TJ,
    3. Sohn CH,
    4. Han MH, et al

    . Effect of delayed transit time on arterial spin labeling: correlation with dynamic susceptibility contrast perfusion magnetic resonance in Moyamoya disease. Invest Radiol 2013;48:795–802 doi:10.1097/RLI.0b013e3182981137 pmid:23764569

    CrossRefPubMed
18. 18.↵
    2. MacIntosh BJ,
    3. Lindsay AC,
    4. Kylintireas I, et al

    . Multiple inflow pulsed arterial spin-labeling reveals delays in the arterial arrival time in minor stroke and transient ischemic attack. AJNR Am J Neuroradiol 2010;31:1892–94 doi:10.3174/ajnr.A2008 pmid:20110375

    Abstract/FREE Full Text
19. 19.↵
    2. Wang DJ,
    3. Alger JR,
    4. Qiao JX, et al

    ; UCLA Stroke Investigators. Multi-delay multi-parametric arterial spin-labeled perfusion MRI in acute ischemic stroke: comparison with dynamic susceptibility contrast enhanced perfusion imaging. Neuroimage Clin 2013;3:1–7 doi:10.1016/j.nicl.2013.06.017 pmid:24159561

    CrossRefPubMed
20. 20.↵
    2. Bokkers RP,
    3. Bremmer JP,
    4. van Berckel BN, et al

    . Arterial spin labeling perfusion MRI at multiple delay times: a correlative study with H(2)(15)O positron emission tomography in patients with symptomatic carotid artery occlusion. J Cereb Blood Flow Metab 2010;30:222–29 doi:10.1038/jcbfm.2009.204 pmid:19809464

    CrossRefPubMed
21. 21.↵
    2. Chalela JA,
    3. Alsop DC,
    4. Gonzalez-Atavales JB, et al

    . Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. Stroke 2000;31:680–87 doi:10.1161/01.STR.31.3.680 pmid:10700504

    Abstract/FREE Full Text
22. 22.↵
    2. Dai W,
    3. Shankaranarayanan A,
    4. Alsop DC

    . Volumetric measurement of perfusion and arterial transit delay using Hadamard encoded continuous arterial spin labeling. Magn Reson Med 2013;69:1014–22 doi:10.1002/mrm.24335 pmid:22618894

    CrossRefPubMed
23. 23.↵
    2. Alsop DC,
    3. Detre JA

    . Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab 1996;16:1236–49 doi:10.1097/00004647-199611000-00019 pmid:8898697

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Dai W,
    3. Robson PM,
    4. Shankaranarayanan A, et al

    . Reduced resolution transit delay prescan for quantitative continuous arterial spin labeling perfusion imaging. Magn Reson Med 2012;67:1252–65 doi:10.1002/mrm.23103 pmid:22084006

    CrossRefPubMed
25. 25.↵
    2. Buxton RB,
    3. Frank LR,
    4. Wong EC, et al

    . A general kinetic model for quantitative perfusion imaging with arterial spin labeling. Magn Reson Med 1998;40:383–96 doi:10.1002/mrm.1910400308 pmid:9727941

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Wang J,
    3. Alsop DC,
    4. Li L, et al

    . Comparison of quantitative perfusion imaging using arterial spin labeling at 1.5 and 4.0 Tesla. Magn Reson Med 2002;48:242–54 doi:10.1002/mrm.10211 pmid:12210932

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Martí-Fàbregas JA,
    3. Catafau AM,
    4. Marí C, et al

    . Cerebral perfusion and haemodynamics measured by SPET in symptom-free patients with transient ischaemic attack: clinical implications. Eur J Nucl Med 2001;28:1828–35 doi:10.1007/s00259-001-0656-6 pmid:11734922

    CrossRefPubMed
28. 28.↵
    2. Landis JR,
    3. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 doi:10.2307/2529310 pmid:843571

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Gibbs JM,
    3. Wise RJ,
    4. Leenders KL, et al

    . Evaluation of cerebral perfusion reserve in patients with carotid-artery occlusion. Lancet 1984;1:310–14 pmid:6141382

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Schumann P,
    3. Touzani O,
    4. Young AR, et al

    . Evaluation of the ratio of cerebral blood flow to cerebral blood volume as an index of local cerebral perfusion pressure. Brain 1998;121(pt 7):1369–79 doi:10.1093/brain/121.7.1369 pmid:9679787

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Eicker SO,
    3. Turowski B,
    4. Heiroth HJ, et al

    . A comparative study of perfusion CT and 99m Tc-HMPAO SPECT measurement to assess cerebrovascular reserve capacity in patients with internal carotid artery occlusion. Eur J Med Res 2011;16:484–90 doi:10.1186/2047-783X-16-11-484 pmid:22027641

    CrossRefPubMed
32. 32.↵
    2. Kawano T,
    3. Ohmori Y,
    4. Kaku Y, et al

    . Prolonged mean transit time detected by dynamic susceptibility contrast magnetic resonance imaging predicts cerebrovascular reserve impairment in patients with Moyamoya disease. Cerebrovasc Dis 2016;42:131–38 doi:10.1159/000445696 pmid:27088711

    CrossRefPubMed
33. 33.↵
    2. Park JC,
    3. Kim JE,
    4. Kang HS, et al

    . CT perfusion with angiography as a substitute for both conventional digital subtraction angiography and acetazolamide-challenged SPECT in the follow-up of postbypass patients. Cerebrovasc Dis 2010;30:547–55 doi:10.1159/000319026 pmid:20948198

    CrossRefPubMed
34. 34.↵
    2. Kim JH,
    3. Lee SJ,
    4. Shin T, et al

    . Correlative assessment of hemodynamic parameters obtained with T2*-weighted perfusion MR imaging and SPECT in symptomatic carotid artery occlusion. AJNR Am J Neuroradiol 2000;21:1450–56 pmid:11003277

    Abstract/FREE Full Text
35. 35.↵
    2. Yun TJ,
    3. Paeng JC,
    4. Sohn CH, et al

    . Monitoring cerebrovascular reactivity through the use of arterial spin labeling in patients with Moyamoya disease. Radiology 2016;278:205–13 doi:10.1148/radiol.2015141865 pmid:26197057

    CrossRefPubMed
36. 36.↵
    2. Moreton FC,
    3. Dani KA,
    4. Goutcher C, et al

    . Respiratory challenge MRI: practical aspects. Neuroimage Clin 2016;11:667–77 doi:10.1016/j.nicl.2016.05.003 pmid:27330967

    CrossRefPubMed
37. 37.↵
    2. Vorstrup S,
    3. Henriksen L,
    4. Paulson OB

    . Effect of acetazolamide on cerebral blood flow and cerebral metabolic rate for oxygen. J Clin Invest 1984;74:1634–39 doi:10.1172/JCI111579 pmid:6501565

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Murase K,
    3. Tanada S,
    4. Fujita H, et al

    . Kinetic behavior of technetium-99m-HMPAO in the human brain and quantification of cerebral blood flow using dynamic SPECT. J Nucl Med 1992;33:135–43 pmid:1730979

    Abstract/FREE Full Text
39. 39.↵
    2. Martin SZ,
    3. Madai VI,
    4. von Samson-Himmelstjerna FC, et al

    . 3D GRASE pulsed arterial spin labeling at multiple inflow times in patients with long arterial transit times: comparison with dynamic susceptibility-weighted contrast-enhanced MRI at 3 Tesla. J Cereb Blood Flow Metab 2015;35:392–401 doi:10.1038/jcbfm.2014.200 pmid:25407272

    CrossRefPubMed
40. 40.↵
    2. Inugami A,
    3. Kanno I,
    4. Uemura K, et al

    . Linearization correction of 99mTc-labeled hexamethyl-propylene amine oxime (HM-PAO) image in terms of regional CBF distribution: comparison to C15O2 inhalation steady-state method measured by positron emission tomography. J Cereb Blood Flow Metab 1988;8:S52–60 doi:10.1038/jcbfm.1988.33 pmid:3142888

    CrossRefPubMed
41. 41.↵
    2. Fan AP,
    3. Jahanian H,
    4. Holdsworth SJ, et al

    . Comparison of cerebral blood flow measurement with [15O]-water positron emission tomography and arterial spin labeling magnetic resonance imaging: a systematic review. J Cereb Blood Flow Metab 2016;36:842–61 doi:10.1177/0271678X16636393 pmid:26945019

    CrossRefPubMed